Navigation Links
goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
Date:1/11/2012

SAN FRANCISCO, Jan. 11, 2012 /PRNewswire/ -- goBalto, developer of new generation web-based clinical research solutions, announced that it successfully completed a FDA 21 CFR Part 11 compliance audit of its goBalto Tracker™ Software-as-a-Service (SaaS) clinical trials application. Tracker's successful audit will help both sponsors / clinical research organizations and investigator sites running clinical trials comply with FDA rules and regulations governing electronic records and electronic signatures.

"The Tracker application demonstrated compliance with the current 21 CFR Part 11 industry standards feature set for security, data transfer, audit trails, and electronic signatures. No deficiencies were found. The implementation of security and electronic signature components is elegant and sets a new standard for web-based GxP applications," said David Nettleton, principal at Computer System Validation, who conducted the audit.

goBalto and David Nettleton found innovative ways to balance 21 CFR Part 11 compliance requirements with cutting-edge Agile software development practices, facilitating rapid response from the feedback of clinical trial professionals.

About goBalto

goBalto is a developer of new generation web-based solutions that simplify how clinical trials are conducted in the pharmaceutical, biotechnology and medical device industries. Tracker™, launched in June 2011, is the first purpose-built Software-as-a-Service clinical research tool that enables clinical trials sponsors and clinical research organizations to collaborate with multiple partners directly from the web in a transparent and regulatory compliant manner. Founded in Silicon Valley in 2008 by biotechnology industry veteran Jae Chung and backed by leading health technology investors, goBalto applies Agile and lean startup methodologies to building technological solutions that address evolving global healthcare. Visit www.gobalto.com for more information.

About David Nettleton:

David Nettleton, principal at Computer System Validation, is an industry leader, author, and teacher for 21 CFR Part 11, Annex 11, HIPAA, software validation, and computer system validation. He is involved with the development, purchase, installation, operation and maintenance of computerized systems used in FDA compliant applications. His most popular book is Risk Based Software Validation – Ten easy Steps (Davis Horwood International and PDA – www.pda.org, 2006), which provides fill-in-the-blank templates for completing a COTS software validation project. He has completed more than 205 mission critical laboratory, clinical, and manufacturing software implementation projects.

 


'/>"/>
SOURCE goBalto
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. goBalto Introduces Web-based Solution to Manage Drug-development Collaborations
2. goBalto Drug Development Partnering WebSite to Include Clinical Trials Support's List of Investigator Sites
3. goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites
4. MiMedx Group Completes $5,000,000 Private Placement
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. CeNeRx BioPharma Completes $4.85 Million Financing
7. Aratana Therapeutics Completes $15 Million Series B Financing
8. InnoPharma Completes $15 Million Series A Financing
9. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
10. Agendia Successfully Completes Bi-Annual FDA Inspection
11. HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... ) today announced the submission of a Marketing Authorization Application ... a biosimilar candidate to Avastin ® (bevacizumab). The companies ... to the EMA. "The submission of ABP ... seeks to expand our oncology portfolio," said Sean E. ...
(Date:12/2/2016)... ... , ... ACEA Biosciences, Inc. announced today that it will be presenting updated ... World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR T790M ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... (CSS) and the popularity of US Single Day Events (SDE) to organize a ... Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life sciences industry ...
(Date:12/2/2016)... IL (PRWEB) , ... December 01, 2016 , ... ... to congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance ... cleared a significant hurdle in commercializing remote cardiac monitoring devices that rely on ...
Breaking Biology Technology:
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):